Intec Pharma (NTEC) Receives a Hold from Maxim Group
Maxim Group analyst Jason McCarthy maintained a Hold rating on Intec Pharma (NTEC) yesterday. The company’s shares closed last Friday at $3.13, close to its 52-week low of $2.20.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 32.7% and a 45.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Interpace Diagnostics Group.
Intec Pharma has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
The company has a one-year high of $15.82 and a one-year low of $2.20. Currently, Intec Pharma has an average volume of 234.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.